ArticleBMC infectious diseases2025
Analysis of pertussis surveillance data (2022-2023) in a district of Beijing.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metagenomic and Targeted Next-Generation Sequencing in Infectious Disease Diagnostics: Current Applications, Challenges, and Future Perspectives.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study describes the epidemiological and drug resistance characteristics of Bordetella pertussis (B. pertussis) isolated from chronic/protracted cough patients in Beijing, China.
methodsA total of 160 patients with chronic/protracted cough from two hospitals in Beijing from 2022 to 2023 were enrolled in this study. Culture, real-time PCR assays and anti-pertussis toxin IgG antibody (PT-IgG) determination were used to confirm the pertussis diagnosis. Forty samples collected between September and November 2023 were screened for 200 respiratory pathogens via targeted next-generation sequencing (tNGS). Antimicrobial susceptibility testing for B. pertussis strains was performed via the E test.
resultsIn this study, 98 patients were diagnosed with laboratory-confirmed cases of pertussis, for a diagnosis rate of 61.25% (98/160). The number of enrolled cases and laboratory-confirmed cases of pertussis increased from July to December 2023, and the highest number of enrolled and laboratory-confirmed cases of pertussis were observed in the age group of 6–12 years. In total, 49 B. pertussis isolates were derived from chronic/protracted cough patients, and the MICs of clindamycin (> 256 µg/mL), erythromycin (> 256 µg/mL), azithromycin (> 256 µg/mL) and sulfamethoxazole (> 1024 µg/mL) were greater than the maximum tested concentrations. B. pertussis-related gene fragments were detected in 17 samples via tNGS, with a detection rate of 42.50% (17/40).
conclusionsPatients with chronic/protracted cough in this region have a high rate of laboratory-confirmed pertussis. It is important to collect multiple samples during the course of pertussis, as well as to apply various pathogenetic and serologic methods to improve laboratory-based pertussis surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.